New epilepsy drug candidate iQ-007 enters first human safety trial
NCT ID NCT06899230
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety of an experimental oral drug called iQ-007 in 72 healthy volunteers. The drug is designed to help control seizures by boosting the brain's ability to clear excess glutamate, a chemical linked to epilepsy. The study does not yet test if it works for seizures, only whether it is safe and how the body processes it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iQ-007 (an experimental oral drug that may help control seizures by boosting glutamate transport in the brain)
What this could lead to
If safe and effective in later trials, iQ-007 could become a new treatment option for people with drug-resistant epilepsy and focal seizures.
What could go wrong
This is an early Phase 1 safety study in only 72 healthy people, not patients. It does not test if the drug actually works for epilepsy, and many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG RESISTANT EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMAX Clinical Research Pty Ltd
Adelaide, South Australia, 5000, Australia